OPCH Rockets 33% as McKesson, CD&R Sign $5B Buyout
Option Care Health surges 33% to $31 after McKesson and Clayton Dubilier & Rice sign a $5B-plus acquisition deal. What traders need to know before the close.
Key Points
- McKesson and private equity firm Clayton Dubilier & Rice have signed an agreement to acquire Option Care Health in a deal valued at more than $5 billion, sending OPCH shares up 32.65% to $31.00 on volume of 65 million shares — more than 21 times the three-month average.
- The deal gives McKesson direct ownership of the largest independent home and alternate-site infusion services provider in the United States, deepening its vertical integration beyond drug distribution.
- At $31, OPCH is still below its 52-week high of $36.80, leaving room for a bump bid — traders should watch whether a competing offer or improved terms emerge before deal close.
McKesson and Clayton Dubilier & Rice have signed an agreement to acquire Option Care Health in a transaction valued at more than $5 billion, the Financial Times reported Wednesday morning — and the market moved immediately. OPCH shares surged 32.65% to $31.00 on volume of 65 million shares, against a three-month daily average of roughly 3 million. That volume ratio — more than 21 times normal — signals this is not a rumor trade or a speculative position squeeze. Institutions are repricing the equity for a deal that is, by all available reporting, done.
Why McKesson Wants This Asset
Option Care Health is not a name that commands headlines on a normal Wednesday, but it is precisely the kind of asset that a drug distribution giant like McKesson pays a strategic premium to control. OPCH is the largest independent provider of home and alternate-site infusion therapy in the United States, operating more than 170 locations across 49 states and managing complex drug regimens for patients with conditions including cancer, immune disorders, and heart failure. The infusion services market sits at the intersection of two powerful demographic and economic trends: an aging U.S. population with rising rates of chronic illness, and a sustained push by payers — both commercial insurers and Medicare — to shift high-cost inpatient procedures to lower-cost home settings.
McKesson's core business is pharmaceutical distribution — moving drugs from manufacturers to hospitals, pharmacies, and clinics at scale. Acquiring OPCH extends that vertical integration one critical step further, giving McKesson direct control over the point of care for some of the most expensive specialty drugs in its distribution network. Specialty pharmaceuticals — oncology agents, biologics, immunology drugs — already account for a disproportionate share of drug spend growth in the United States, and many of them are administered intravenously, which is exactly OPCH's core competency. This is not a financial engineering deal. It is a strategic land grab for a capability McKesson cannot easily build organically at OPCH's scale.
The involvement of Clayton Dubilier & Rice adds a layer of financial structure that is worth understanding. CD&R is not a passive capital provider here — the firm has a track record of acquiring healthcare services businesses, improving operating margins through scale and procurement efficiency, and ultimately exiting at premium valuations. The joint acquisition structure with McKesson suggests a deal in which CD&R likely holds a meaningful equity stake alongside MCK, possibly with a defined path for McKesson to acquire the remaining interest over a multi-year horizon. That structure is common in large healthcare services transactions where regulatory approval timelines and integration complexity make a staged acquisition more practical than an outright purchase.
Reading the Price Gap
At $31.00, OPCH is trading significantly below its 52-week high of $36.80 — a gap of 15.8% that experienced merger arbitrage traders will immediately recognize as a potential signal. In most signed buyout transactions, the acquirer pays a premium to the undisturbed stock price, and the deal price is typically disclosed at announcement. The Financial Times reporting Thursday evening described the transaction as valued at "more than $5 billion," but did not specify a per-share price. With approximately 150 million diluted shares outstanding, a $5 billion deal implies a price of roughly $33.33 per share — about 7.5% above Wednesday's close of $31.00. A $5.5 billion deal implies $36.67, nearly touching the 52-week high.
That math is why OPCH at $31 is not a clean hold-and-wait situation for all traders. The spread between the current price and the implied deal price depends entirely on a number that has not yet been publicly confirmed: the per-share offer. If the transaction closes at $33 to $34, buyers at $31 capture 6% to 10% in what could be a three-to-six month holding period — a reasonable merger arb return. If the deal includes a go-shop period and a competing bid emerges — perhaps from a rival distributor like AmerisourceBergen or a strategic buyer in the specialty pharmacy space — the ceiling could be considerably higher. The 52-week high of $36.80 is the upper bound on rational bump speculation.
The risk side of the equation deserves equal attention. Regulatory scrutiny of healthcare consolidation has intensified since 2024, and a McKesson–OPCH combination touches both distribution and care delivery, which could attract antitrust review from the FTC's healthcare division. Financing risk is real but manageable — McKesson's balance sheet is investment-grade and CD&R has the dry powder for a deal of this size, but any deterioration in credit markets between signing and close creates execution uncertainty. Volume at 65 million shares suggests the market is largely pricing in a clean close, which means the downside on a deal break — back toward the pre-announcement price of roughly $23 — is severe. Traders sizing into OPCH at $31 are making a judgment that deal certainty justifies the asymmetric tail risk.
What the Timeline Looks Like
The practical question for traders holding OPCH overnight is when the formal deal terms get disclosed. In a signed transaction, a press release or SEC filing with specific per-share consideration typically follows within 24 to 48 hours of media reporting. If McKesson files an 8-K or OPCH issues a merger proxy timeline before Thursday's open, the spread math gets substantially cleaner. The absence of a specific price in Wednesday's reporting is the single largest source of uncertainty in this trade — and the most important catalyst to monitor in the next 12 hours.
McKesson's acquisition strategy has been consistently focused on building out its specialty and oncology services platforms over the past three years, and OPCH fits cleanly into that framework. The company's existing Ontada oncology data platform and its US Oncology Network already serve as models for the kind of integrated care delivery McKesson is assembling — OPCH's infusion infrastructure would add a complementary channel serving a partially overlapping patient population. For MCK shareholders, the deal is strategically coherent if the price is disciplined; the stock's reaction Wednesday was muted relative to OPCH, which is typical when the acquirer is a large-cap strategic buyer absorbing a transaction of manageable relative size.
The broader healthcare M&A context also matters. Specialty care and alternate-site infusion have been active consolidation targets throughout 2025 and 2026, as hospital systems, distributors, and insurers all compete to own the care pathway for high-cost chronic conditions. The Option Care Health deal — if it closes at the valuations implied by the $5 billion-plus headline — will likely accelerate that consolidation by confirming the premium the market assigns to scaled infusion operators. Smaller independent infusion providers could see renewed M&A interest as a direct consequence. Watch for the formal per-share price disclosure on Thursday — that number resolves the trade.
The Weekly Investor
Daily market analysis for active traders. Free.
